Advancing Blood Disorder Treatments Through Precision Therapeutics

Advancing Blood Disorder Treatments Through Precision Therapeutics

Author: American Society of Hematology November 20, 2025 Duration: 15:08

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Terri Parker and Peter Lenting on their latest papers published in Blood Journal. Dr. Lenting discusses his work on introducing a new therapeutic approach to von Willebrand disease with the development of a novel bispecific antibody (KB-V13A12) that links endogenous mouse VWF to albumin, extending VWF half-life twofold with cessation of provoked bleeding. Dr Parker shares the results of a 43-patient phase 2 study that evaluates the single agent isatuximab, a CD38 monoclonal antibody, in patients with relapsed/refractory AL amyloidosis. With a hematological response rate of 77%, organ response rates between 50 and 57%, and an excellent safety profile, the current study lays the foundation for future use of isatuximab across treatment settings and combination strategies.

Featured Articles


Produced by the American Society of Hematology, the Blood Podcast serves as an audio companion to the groundbreaking research found in its namesake journal. Each episode delves into the latest published studies, translating complex findings on blood disorders, cancers, and immune system functions into accessible discussions. You'll hear directly from the researchers and clinicians who are shaping the field, as they break down their methodologies, interpret results, and explore the real-world implications for patient care. This isn't just a summary; it's a critical conversation that examines the how and why behind the science, offering context that the printed page alone cannot provide. Whether you're a practicing hematologist, a trainee in the field, or simply fascinated by the intricate world of human biology, this podcast provides a vital stream of knowledge. It connects the dots between laboratory discovery and clinical practice, all while exploring topics that span from foundational biology to cutting-edge therapeutic advances. Tune in for a thoughtful analysis that makes the latest hematology research comprehensible and immediately relevant to your work or curiosity.
Author: Language: English Episodes: 50

Blood Podcast
Podcast Episodes
Dose Makes the Cure: Venetoclax in Ph- ALL [not-audio_url] [/not-audio_url]

Duration: 14:21
In this week's episode, Blood editor Dr. James Griffin interviews Dr. Jianxiang Wang from the National Clinical Research Center for Blood Diseases and the Institute of Hematology and Blood Diseases Hospital, Chinese Acad…
MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow [not-audio_url] [/not-audio_url]

Duration: 24:34
In this week's episode, Blood editor Dr. James Griffin interviews Drs. Thomas Milne and Dominique Bonnet on their latest articles published in volume 147 issue 24 of Blood. Dr. Milne discusses how transcription factors s…
Predictive Markers of Glofitamab Resistance in R/R B-NHL [not-audio_url] [/not-audio_url]

Duration: 15:41
In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Camille Laurent and Christine Bezombes on their latest article published in Blood titled "Patient-derived lymphoma spheroids reveal predictive markers…
FLT3-ITD microclones in AML and Results from the RESET-PV trial [not-audio_url] [/not-audio_url]

Duration: 13:48
In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Pierre-Yves Dumas and Samik Basu on their latest articles published in Blood. Dr. Dumas talks about "Prognostic impact of FLT3-ITD microclones in y…
Initial CHORUS data on HHT and ASH HematOmics Program [not-audio_url] [/not-audio_url]

Duration: 26:14
In this week's episode, Blood editor Dr. James Griffin interviews Drs. Hanny Al-Samkari and Xin Zhou on their latest articles published in Blood. This episode highlights two important advances in hematology: the first re…